Article History
Accepted: 25 January 2021
First Online: 2 March 2021
Competing interests
: B.L.E. has received research funding from Celgene, Deerfield and Novartis, and consulting fees from GRAIL. He serves on the scientific advisory boards and holds equity in Exo Therapeutics, Neomorph Therapeutics and Skyhawk Therapeutics. M.J. and A.S.S. declare no competing interests.